In this review
The included appointment makes this a different purchase
The Advanced Panel lists 71 biomarkers and a thirty-minute clinician consultation for $399. The described pathway is a blood draw followed by a link to book a results visit. That appointment is a practical distinction from buying a test and then arranging someone else to interpret it. [1]
I would still begin with the clinical question. A broader hormone, metabolism and thyroid panel has value when its results can change a considered plan. A long biomarker list does not establish that every measurement is necessary, and a normal-range flag or biological-age estimate is not itself an improvement in health.
Keep a measurement separate from a validated outcome in the biological-age testing evidence.
Repeated testing adds appointments and a larger purchase
The same page lists two annual labs at $798 and four at $1,596. Those packages do not become a universal recommendation to retest that often. Confirm the payment timing, number of included results consultations and schedule for the selected option before committing to repeated collection. [1]
Collection is described through a local laboratory or Quest, with home collection where available. For serviceable New York, New Jersey and Rhode Island addresses, the page offers a mobile venous draw for an additional $99. A different at-home hormone kit is offered for qualifying NJ/RI collection limitations; do not assume it duplicates this panel. [1]
Compare collection, appointments and repeat costs in the health-service cost planner.
A results discussion does not bundle every treatment
The platform also sells hormone, NAD+, sermorelin and weight-care programs. These are separate catalogue purchases, not automatic inclusions in the Advanced Panel. Coaching and unlimited messaging can support follow-up, but neither a test result nor a clinician consultation guarantees a prescription or makes a further treatment necessary. [1] [2]
The terms distinguish third-party clinical providers and pharmacies from the platform. They also describe a three-month minimum and thirty-day cancellation notice for subscriptions. Establish whether the selected lab package recurs and what agreement applies, while keeping medication, additional testing and primary care costs separate. [3]
For a different prescription-focused service scope, read our Levers individual-program review.
For a different supply purchase and clinical-support arrangement, compare our AquaVita purchase-and-care review.
Final-sale testing deserves a decision before the blood draw
The general policy makes diagnostic labs and lab subscriptions final sale. The panel’s expanded collection notice separately promises a refund for issues with its described location arrangements. Clarify that exception before ordering; it is not an ordinary change-of-mind refund. Compare a narrower test when one specific marker is the unresolved need. [1] [4]
FDA’s June 2026 letter concerned the platform’s compounded GLP-1 advertising and labeling. It was not a finding about this panel’s analytical accuracy; the letter alone does not establish later closure. Keep that regulatory history specific while judging the lab purchase by its actual tests, usable consultation and complete collection cost. [5]
For a narrower test with a different follow-up arrangement, compare our Everlywell lipid-kit review.
Understanding the cost
Advanced Panel: one lab $399; two annual labs $798; four annual labs $1,596. A 30-minute clinician consultation is included. Serviceable NY/NJ/RI mobile venous draw adds $99. Confirm package billing and collection; general final-sale policy has a stated location-issue refund exception.
Build your cost estimateSources
- Joi + Blokes: Advanced Panel price, included consultation and collection conditions
- Joi + Blokes: separate current diagnostic and treatment products
- Joi + Blokes: subscription minimum, cancellation notice and clinical roles
- Joi + Blokes: prescription, insurance-program and diagnostic-lab refund policy
- FDA June 8, 2026: Joi + Blokes compounded GLP-1 advertising and labeling letter
This review evaluates public service information. It does not claim patient enrollment, product testing or measurement of clinical outcomes.